SHPH

3.49010.51%
MJ

Mira Jung

Co-Founder & Chief Scientific Officer for Biology

Dr. Mira Jung, Ph.D, co-founded Shuttle Pharmaceuticals, LLC in December 2012 and has been its Chief Scientific Officer for Biology and previously served as Director from December 2012 until 2019. Dr. Jung serves as Associate Professor of Department of Radiation Medicine and Microbiology, Georgetown University School of Medicine. Dr. Jung serves as Director of Molecular Radiation Biology Lab. She served as a Member of Scientific Advisory Board of Rexahn Pharmaceuticals, Inc. With experience in molecular radiation biology research, she is an expert in mechanisms of radiation resistance and on the roles of HDAC inhibitors in modifying the radiation response. Dr. Jung is a Co-Founder of Shuttle Pharmaceuticals Holdings, Inc. Dr. Jung served as a Member of the Board of Directors from December 2012 until 2019. Since 2005, Dr. Jung has held the position of Professor of Radiation Medicine and Microbiology at Georgetown University Medical School. In his role, he provides valuable experience and expertise in the discovery and development of new HDAC inhibitors and their pre-clinical evaluation. He is also recognized for his contributions to innovation, holding six issued patents. Dr. Jung’s research has been funded by NIH and the DOD leading to 100+ publications and nine patents granted by the USPTO, including the first reports of HDAC inhibitor drug classes modifying cancer cell radiation resistance and protecting normal tissues from radiation damage. Dr. Jung holds an MA degree and a PhD in Microbiology and Molecular Virology from the University of Kansas, Lawrence.

Positions